Dassault

French pharmaceutical company Ipsen has collaborated with Dassault Systèmes to develop new and effective programmes to support its drug discovery.

Under the terms, Ipsen will deploy Dassault’s 3DEXPERIENCE platform to accelerate its research and development (R&D), transformation and discovery of new therapeutic solutions.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The 3DEXPERIENCE platform is a business experience platform that is available on premises and in public or private cloud, Dassault said.

It offers data integration, modelling and simulation capabilities to better understand dysregulations linked to diseases.

The 3DEXPERIENCE platform also improves and shortens the identification of quality drug candidates.

Dassault Systèmes life sciences industry vice-president Jean Colombel said: "The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"The 3DEXPERIENCE platform also improves and shortens the identification of quality drug candidates."

"Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences."

The project also aims to optimise the R&D processes of Ipsen’s multi-disciplinary teams in the biotechnological and life sciences hubs in France, the UK and the US.

Ipsen R&D executive vice-president Claude Bertrand said: "After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools.

"Ipsen as a key scientific partner has open innovation in its DNA and this new collaborative and innovative digital platform will support Ipsen’s commitment to achieve therapeutic breakthroughs in patient care."

Ipsen primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders.

Image: 3DEXPERIENCE platform improves and shortens the identification of quality drug candidates. Photo: courtesy of Dassault Systèmes.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact